Akebia Therapeutics, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (29)

Latest Posts

About This Stock More About This Stock
Research Report: Akebia Therapeutics, Inc.
Article By: Elle Investments
Saturday, April 20, 2019 3:11 PM EST
As of 4Q18, AKBA had cash of $322M. Additionally, AKBA is eligible to receive over $150M in development and regulatory milestones from its collaboration partners.
In this article: AKBA
Read
Akebia Therapeutics, Inc. Shares Shoot Up On Announcement Of Collaboration With Otsuka
Article By: TickerTV
Wednesday, April 26, 2017 8:45 AM EST
AKBA opened trading yesterday at $9.38 which was up from the previous day’s trading close of $9.31. Shares closed trading yesterday at $9.37 and spiked up after market to $12.25, equivalent to a 31% increase from the closing price.
In this article: AKBA
Read
Seven Biotech Names On The Upswing: 2016 Small-Cap Biotech Watchlist Update
Article By: The Life Sciences Report
Wednesday, March 9, 2016 5:47 PM EST
Biotech stocks—and the stock market in general—took a dive at the beginning of 2016, headed down on macroeconomic factors such as financial instability in China.
In this article: SGYP, CRMD, ORMP, SRNE, ARRY, PTIE, AGEN, GALE, PPHM, EVOK, ADMA, AKBA, KPTI, VSTM, AST, RXDX, AGTC, WVE, FATE, FLKS, PIRS, ABEO
Read
The 2016 Small-Cap Biotech Watchlist Debuts At The Biotech Showcase
Article By: The Life Sciences Report
Wednesday, January 27, 2016 6:16 PM EST
This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's 2016 Small-Cap Biotech Watchlist believe these companies have a good producing value for investors.
In this article: AZN, NVO, SGYP, SNY, CRMD, ORMP, CMXHY, SRNE, ALNY, ARRY, INCY, IRWD, PTIE, REGN, VRTX, AGEN, GALE, GRFS, PPHM, EVOK, ADMA, AKBA, VSTM, AST, RXDX, AGTC, NK, WVE, FATE, FLKS
Read
E Akebia Therapeutics: A Trade Opportunity With A Catalyst Ahead?
Article By: M.E. Garza
Thursday, October 2, 2014 9:26 AM EST
With shares trading within a technical range and an upcoming catalyst ahead, it may be time to look for a trade opportunity via Akebia Therapeutics.
In this article: AKBA
Read

PARTNER HEADLINES

Latest Tweets for $AKBA

No tweets yet!